MAPT and tauopathy: Although there are new tau-PET tracers emerging that show potential inthe 4R tauopathies, these are not yet validated for use in the clinic setting,17,18 and in the absence of a validated tau-PET tracer for PSP, structuralMRI offers an indirect measure of underlying tau pathology in vivo.